QLGN Key Statistics, Chart & Performance
The current stock price of QLGN is 3.21 USD. In the past month the price decreased by -15.97%. In the past year, price decreased by -33.55%.
QLGN Latest News, Press Relases and Analysis
QLGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.29 | 405.44B | ||
| AMGN | AMGEN INC | 15.29 | 179.97B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 155.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.42 | 108.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.92 | 80.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 851.43 | 56.92B | ||
| INSM | INSMED INC | N/A | 43.74B | ||
| NTRA | NATERA INC | N/A | 32.75B | ||
| BIIB | BIOGEN INC | 10.56 | 25.92B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.08 | 21.58B | ||
| INCY | INCYTE CORP | 16.55 | 20.75B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.12B |
Related stock screener links
About QLGN
Company Profile
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company is headquartered in Carlsbad, California. The company went IPO on 2015-06-24. The firm is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.
Company Info
QUALIGEN THERAPEUTICS INC
2042 Corte Del Nogal
Carlsbad CALIFORNIA 92011 US
CEO: Andrew J. Ritter
Employees: 4
Phone: 17609189165
QUALIGEN THERAPEUTICS INC / QLGN FAQ
Can you describe the business of QUALIGEN THERAPEUTICS INC?
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company is headquartered in Carlsbad, California. The company went IPO on 2015-06-24. The firm is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.
What is the stock price of QUALIGEN THERAPEUTICS INC today?
The current stock price of QLGN is 3.21 USD. The price increased by 5.59% in the last trading session.
What is the dividend status of QUALIGEN THERAPEUTICS INC?
QLGN does not pay a dividend.
What is the ChartMill rating of QUALIGEN THERAPEUTICS INC stock?
QLGN has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is QUALIGEN THERAPEUTICS INC (QLGN) stock traded?
QLGN stock is listed on the Nasdaq exchange.
Can you provide the number of employees for QUALIGEN THERAPEUTICS INC?
QUALIGEN THERAPEUTICS INC (QLGN) currently has 4 employees.
QLGN Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to QLGN. When comparing the yearly performance of all stocks, QLGN is one of the better performing stocks in the market, outperforming 86.68% of all stocks.
QLGN Financial Highlights
Over the last trailing twelve months QLGN reported a non-GAAP Earnings per Share(EPS) of -8.6. The EPS increased by 83.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -176.92% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
QLGN Forecast & Estimates
For the next year, analysts expect an EPS growth of 62.96% and a revenue growth -100% for QLGN